News Egis intensifies its acquisition strategy in 2017 2017.10.19. Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets. details > Egis is one of the most attractive workplaces in the pharma industry 2017.04.25. Our company was awarded based on the evaluation of employees and job seekers. details > Dr. Klára András will be HR Director of Egis Pharmaceuticals PLC 2017.03.29. from April 1, 2017 details > Egis strengthens presence in Russia by OTC acquisition 2017.02.06 Egis acquired Russian D-Panthenol and women’s health product portfolio from Jadran-Galenski Laboratorij’s (JGL). details > Egis is investor of the month 2016.12.02. The recognition, founded by the Minister of National Economy, is given the investors, SME-s and start-ups which have achieved outstanding results. In December 2016, Egis Pharmaceuticals was awarded “Investor of the month”. details > Egis reports revenue from collaboration with Actavis 2016.11.14. Egis Pharmaceuticals today announced that it has generated $110 million (USD) in revenue related to the collaboration and sale of generic rosuvastatin calcium by Actavis in the United States. details > << < 1 2 > >>